{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm&page=30", "query": { "condition": "Metastasis, Neoplasm", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 10744, "total_pages": 1075, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T15:07:26.724Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03150836", "title": "Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Terence Friedlander, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-10-01", "completion_date": "2024-09-01", "has_results": false, "last_update_posted_date": "2017-10-19", "last_synced_at": "2026-10-24T15:07:26.724Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03150836" }, { "nct_id": "NCT00003711", "title": "Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "San Antonio Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-09", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2013-05-30", "last_synced_at": "2026-10-24T15:07:26.724Z", "location_count": 2, "location_summary": "Fort Sam Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Fort Sam Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003711" }, { "nct_id": "NCT05180799", "title": "A Phase 1/2 Study of BA3071 in Patients With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NSCLC", "Melanoma" ], "interventions": [ { "name": "BA3071", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed (Alimta)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "BioAtla, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2022-08-03", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-06-15", "last_synced_at": "2026-10-24T15:07:26.724Z", "location_count": 9, "location_summary": "Los Angeles, California • Atlanta, Georgia • Dyer, Indiana + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Dyer", "state": "Indiana" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05180799" }, { "nct_id": "NCT00243009", "title": "Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1, "start_date": "2005-06", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2012-05-28", "last_synced_at": "2026-10-24T15:07:26.724Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00243009" }, { "nct_id": "NCT01339663", "title": "Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "autologous tumor cell vaccine", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "GENETIC" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2012-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-10-24T15:07:26.724Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01339663" }, { "nct_id": "NCT02420587", "title": "AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "AMG 208", "type": "DRUG" }, { "name": "Questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2014-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-20", "last_synced_at": "2026-10-24T15:07:26.724Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02420587" }, { "nct_id": "NCT07141706", "title": "A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Solid Tumors" ], "interventions": [ { "name": "DB-1317", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 253, "start_date": "2025-09-23", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-24T15:07:26.724Z", "location_count": 6, "location_summary": "Los Angeles, California • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07141706" }, { "nct_id": "NCT03035630", "title": "Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear-cell Renal Cell Carcinoma", "RCC", "Kidney Cancer", "Clear-cell Kidney Carcinoma" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Guru Sonpavde", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-05-23", "completion_date": "2020-12", "has_results": false, "last_update_posted_date": "2022-02-15", "last_synced_at": "2026-10-24T15:07:26.724Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03035630" }, { "nct_id": "NCT07030712", "title": "A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Neoplasm" ], "interventions": [ { "name": "MK-8294", "type": "DRUG" }, { "name": "CD8 PET Tracer", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2025-07-23", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-24T15:07:26.724Z", "location_count": 4, "location_summary": "Chicago, Illinois • Hackensack, New Jersey • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07030712" }, { "nct_id": "NCT02492711", "title": "Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER-2 Positive Breast Cancer", "Metastatic Neoplasm" ], "interventions": [ { "name": "Margetuximab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Physician's choice of chemotherapy.", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 624, "start_date": "2015-08-24", "completion_date": "2022-06-14", "has_results": true, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-10-24T15:07:26.724Z", "location_count": 62, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 57 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02492711" } ] }